WeVote
Log In

Bill

Bill

A 7517

Requires vehicles operated by public transit authorities to contain opioid antagonists

2025 Regular Session Introduced by Judy Griffin

Requires transit vehicles to carry opioid antagonists (e.g., naloxone) to enable immediate overdose response on buses and trains.

REFERRED TO HEALTH
0
WeVote Research Nonpartisan
Bill Summary · A 7517

Summary of Assembly Bill A-7517

Overview

Assembly Bill A-7517 would require vehicles operated by public transit authorities to contain opioid antagonists. The bill’s objective appears to be enhancing overdose response capabilities on public transit by ensuring on-board access to an opioid antagonist, such as naloxone, for use in emergencies.

Key Details

  • Bill Number: A-7517
  • Title: Requires vehicles operated by public transit authorities to contain opioid antagonists
  • Status: Referred to Health
  • Introduced: April 1, 2025
  • Classification: Bill
  • Primary Sponsor: Judy Griffin
  • Related Bills: A-10715 (prior-session)

Legislative Progress

  • 2025-04-01: Referred to Health (listed twice in the provided material, likely a formatting duplication)

What the Bill Would Do

  • The core provision, as indicated by the title, is to mandate that vehicles operated by public transit authorities carry opioid antagonists. The summary available does not detail:
    • The specific agent(s) required (e.g., naloxone) or the form in which it must be carried (kits, devices, etc.).
    • Quantities, stock management, or replacement/expiry protocols.
    • Training requirements for transit staff or responders on administration.
    • Placement within vehicles, accessibility, and recordkeeping or reporting requirements.
    • Funding or cost-sharing responsibilities for procurements and training.
    • Any exemptions or phased implementation timelines.

Who Would Be Affected

  • Public transit authorities that operate vehicles (e.g., buses, trains, or other on-road/rail vehicles) would be responsible for complying with the requirement.
  • Transit personnel and staff may be affected by any mandated training or administration protocols (if later specified in the bill’s text).
  • Riders could benefit from improved on-site overdose response capabilities.

Implications and Considerations

  • Health/safety impact: Potentially improved immediate response to overdoses in transit settings.
  • Operational impact: Possible procurement, stocking, maintenance, and training obligations for transit agencies.
  • Budget considerations: Likely costs for purchase of antagonists and related supplies, plus any training or oversight requirements; precise fiscal details are not provided in the summary.
  • Policy trajectory: The bill has been referred to the Health committee, indicating health-related considerations will drive further discussion and potential amendments before floor action.

Next Steps

  • Await committee discussion and any proposed amendments in Health.
  • Review the bill’s full text for specific provisions, implementation timeline, funding mechanisms, and any reporting requirements.
  • Consider related legislation (e.g., A-10715 from a prior session) for context on statewide opioid-response measures in transit settings.

This summary reflects the information available from the provided bill details.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.